Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats

Contraception ◽  
2009 ◽  
Vol 79 (6) ◽  
pp. 488-497 ◽  
Author(s):  
Man M. Misro ◽  
Shankar P. Chaki ◽  
Mahesh C. Kaushik ◽  
Deoki Nandan
2006 ◽  
Vol 21 (8) ◽  
pp. 2033-2040 ◽  
Author(s):  
M.Cristina Meriggiola ◽  
S. Cerpolini ◽  
W.J. Bremner ◽  
M.T. Mbizvo ◽  
K.M. Vogelsong ◽  
...  

2003 ◽  
Vol 25 (4) ◽  
pp. 627-643 ◽  
Author(s):  
Mingcan Yu ◽  
Xiaomei Cao ◽  
Jinju Xu ◽  
Xiaolei Wang ◽  
Jing Yang ◽  
...  

1999 ◽  
Vol 84 (10) ◽  
pp. 3642-3647
Author(s):  
Gui-yuan Zhang ◽  
Yi-qun Gu ◽  
Xing-hai Wang ◽  
Yu-gui Cui ◽  
William J. Bremner

2002 ◽  
Vol 87 (2) ◽  
pp. 530-539 ◽  
Author(s):  
Axel Kamischke ◽  
Tanja Heuermann ◽  
Kathrin Krüger ◽  
Sigrid von Eckardstein ◽  
Ilka Schellschmidt ◽  
...  

2009 ◽  
Vol 94 (6) ◽  
pp. 1910-1915 ◽  
Author(s):  
Yiqun Gu ◽  
Xiaowei Liang ◽  
Weixiong Wu ◽  
Minli Liu ◽  
Shuxiu Song ◽  
...  

Abstract Context: Hormonal male contraceptive regimens effectively and reversibly suppress sperm production, but there are few large-scale efficacy studies. Objective: The safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive was assessed. Design: This was a multicenter, phase III, contraceptive efficacy clinical trial. Participants: A total of 1045 healthy fertile Chinese men were recruited throughout China into the study. Intervention(s): Injections of 500 mg TU were administered monthly for 30 months. A definition of severe oligozoospermia (≤1 × 106/ml) was used as a criterion of spermatogenic suppression and as the threshold for entering the contraceptive efficacy phase. Main Outcome Measure(s): The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests. Results: Forty-three participants (4.8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1554.1 person-years of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1.1 per 100 men. The combined method failure rate was 6.1%, comprising 4.8% with inadequate suppression and 1.3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants. Conclusions: Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.


Sign in / Sign up

Export Citation Format

Share Document